Drug-eluting stents in coronary interventions

Hellenic Journal of Cardiology

Volumn 45, Issue 3, 2004, Pages 140-144

  Voudris, Vassilis ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Balloon angioplasty; Coronary angioplasty; Coronary stenting; Restenosis; Stents

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; POLYMER; PROTEIN P27; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANGIOGRAPHY; ARTERY INTIMA PROLIFERATION; BALLOON CATHETER; CAUSE OF DEATH; CELL CYCLE PHASE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DNA REPLICATION; DNA SYNTHESIS; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; ENDOTHELIUM LESION; ENZYME INHIBITION; HEART INFARCTION; HUMAN; HYPERTENSION; MICROTUBULE ASSEMBLY; MITOSIS; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 30944448822     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (25)

1. American Heart Association, 2002 heart and stroke statistical update. Dallas: American Heart Association, 2001.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495.
3. Serruys PW, Kay P, Disco C, Deshpande NV, de Feyter PJ: Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of meta-analysis of the Belgian Netherlands Stent Study (BENESTENT) I; BENESTENT II and MUSIC trials. J Am Coll Cardiol 1999; 34:1067-1074.
4. Moer R, Myreng Y, Molstald P, Albertsson P, Gunnes P, Lindvall B, et al: Stenting in small coronary arteries (SISCA) trial: a randomized comparison between balloon angioplasty and the heparin coated stent. J Am Coll Cardiol 2001; 38: 1598-1603.
5. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R: Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002; 105: 2974-2980.
6. Bennett MR, O'Sullivan M: Mechanism of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 2001; 91: 149-166.
7. Vom Dahl J, Dietz U, Haager P, Silber S, Niccoli L, Buettner HJ, et al: Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-stent Restenosis Trial (ARTIST). Circulation 2002; 105: 583-588.
8. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER Study). Circulation 1999; 100: 799-806.
9. Holmes D, Savage M, La Blanche JM, Grip L, Serruys PW, Fitzgerald P, et al: Results of Prevention Restenosis with Tranilast and its outcomes (PRESTO) trial. Circulation 2002; 106: 1243-1250.
10. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky A, Janis S, et al: Localized intracoronary gamma radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344: 250-256.
11. Waksman R, Raizner A, Yeung AC, Lansky A, Vandertie L for the INHIBIT Investigators: Use of localized intracoronary beta-radiation in treatment of in-stent restenosis: the INHIBIT randomized controlled trial. Lancet 2002; 359: 551-557.
12. Schwartz RS, Edelman E, for the Consensus Committee. Drug-eluting stents in preclinical studies: recommended evaluation from the consensus group. Circulation 2002; 106: 1867-1873.
13. Suzuki T, Kopia G, Hayashi S, Balley LR, Lianos G, Wilensky R, et al: Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188-1193.
14. Marx SO, Marks AR: Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104: 852-855.
15. Rowinski E, Donehower R, Wood A: Drug therapy; Paclitaxel. N Engl J Med 1995; 332: 1004-1014.
16. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al: Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104: 2007-2011.
17. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, et al: Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003; 107: 381-383.
18. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al: RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. N Engl J Med 2002; 346: 1773-1780.
19. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, et al: Persistent inhibition in neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002; 106: 1610-1613.
20. Moses JW, Leon MB, Pompa JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
21. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
22. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al: The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115.
23. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al: TAXUS I: six and twelve-month results from a randomized, double blind trial on a slow release paclitaxel eluting stent to de novo coronary lesions. Circulation 2003; 107: 38-42.
24. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al: Randomized study to assess the effectiveness of slow and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-794.
25. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al: A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.